{"nctId":"NCT02276612","briefTitle":"Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Adolescents","startDateStruct":{"date":"2014-12-03","type":"ACTUAL"},"conditions":["HIV"],"count":60,"armGroups":[{"label":"E/C/F/TAF","type":"EXPERIMENTAL","interventionNames":["Drug: E/C/F/TAF"]}],"interventions":[{"name":"E/C/F/TAF","otherNames":["Genvoya®"]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Currently on a stable antiretroviral regimen for ≥ 6 consecutive months\n* Weight ≥ 35 kg (77 lbs.)\n* Plasma HIV-1 RNA levels \\< 50 copies/mL for ≥ 6 months\n* CD4+ cell count \\> 100 cells/μL\n* No resistance to elvitegravir (EVG), emtricitabine (FTC), lamivudine (3TC) or tenofovir (TFV)\n* Hepatic transaminases (AST and ALT) ≤ 5 x upper limit of normal (ULN)\n* No evidence of current hepatitis B virus (HBV) infection\n* No evidence of current hepatitis C virus (HCV) infection\n\nNote: participants from Gilead Study GS-US-162-0112 were allowed to roll over into this Study GS-US-292-1515 even if they were 18 years or older at the time of screening.\n\nKey Exclusion Criteria:\n\n* A new AIDS-defining condition diagnosed within the 30 days prior to Screening\n* Evidence of active pulmonary or extra-pulmonary tuberculosis disease within 3 months of screening\n* Pregnant or lactating subjects\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Incidence of Treatment-Emergent Serious Adverse Events","description":"The percentage of participants experiencing any treatment-emergent serious adverse event was summarized.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Incidence of Treatment-Emergent Adverse Events","description":"The percentage of participants experiencing any treatment-emergent adverse event was summarized.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Plasma HIV-1 RNA Level < 50 Copies/mL at Week 24 (FDA-defined Snapshot Analysis)","description":"The percentage of participants achieving HIV-1 RNA \\< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Plasma HIV-1 RNA Level < 50 Copies/mL at Week 48 (FDA-defined Snapshot Analysis)","description":"The percentage of participants achieving HIV-1 RNA \\< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CD4 Cell Count at Week 24","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-72","spread":"189.8"},{"groupId":"OG001","value":"-85","spread":"245.9"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CD4 Cell Count at Week 48","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-43","spread":"201.1"},{"groupId":"OG001","value":"-41","spread":"143.0"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CD4 Percentage at Week 24","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"5.46"},{"groupId":"OG001","value":"-0.6","spread":"5.46"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CD4 Percentage at Week 48","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"3.95"},{"groupId":"OG001","value":"-1.1","spread":"7.29"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":50},"commonTop":["Upper respiratory tract infection","Cough","Diarrhoea","Vomiting","Headache"]}}}